(NASDAQ: XNCR) Xencor's forecast annual revenue growth rate of 1.65% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.48%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.37%.
Xencor's revenue in 2025 is $110,493,000.On average, 5 Wall Street analysts forecast XNCR's revenue for 2025 to be $5,727,427,843, with the lowest XNCR revenue forecast at $1,761,548,350, and the highest XNCR revenue forecast at $9,642,715,668. On average, 5 Wall Street analysts forecast XNCR's revenue for 2026 to be $6,401,184,856, with the lowest XNCR revenue forecast at $5,520,692,529, and the highest XNCR revenue forecast at $8,696,411,894.
In 2027, XNCR is forecast to generate $8,727,415,145 in revenue, with the lowest revenue forecast at $6,583,963,113 and the highest revenue forecast at $10,870,867,178.